Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

9 Months Ended

Sep. 30, 2019

Schedule of research and development-licenses

As such, for the three and nine months ended September 30, 2019 and 2018, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations as reflected in the table below:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2019		2018		2019		2018
Fortress Companies:
Helocyte	$	—	$	1,500	$	—	$	1,521
Checkpoint		—		1,000		—		1,000
Caelum		—		201		—		201
Mustang		700		1,000		1,350		1,075
Aevitas		—		5		—		6
Cellvation		—		—		—		1
Total	$	700	$	3,706	$	1,350	$	3,804

Schedule of research and development for licenses acquired

The table below provides a summary of Checkpoint’s expense related to its licenses, for the three and nine months ended September 30, 2019 and 2018 by license as recorded in the Condensed Consolidated Statements of Operations:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2019		2018		2019		2018
Dana Farber License CK-301	$	—	$	1,000	$	—	$	1,000
Total	$	—	$	1,000	$	—	$	1,000

For the three and nine months ended September 30, 2019 and 2018, Mustang recorded the following expenses in research and development for licenses acquired on the condensed consolidated statement of operations:


	Three Months Ended September 30,				Nine Months Ended September 30,
($in thousands)	2019		2018		2019		2018
City of Hope
CD123	$	—	$	—	$	250	$	—
CSI		—		—		200		—
Manufacturing		—		—		—		75
PSCA		200		—		200		—
Calimmune		200		—		200		—
UCLA		300		—		300		—
St. Jude-X-SCID		—		1,000		—		1,000
Nationwide Children's Hospital - C134		—		—		200		—
Total	$	700	$	1,000	$	1,350	$	1,075